Acumen Pharmaceuticals reported a net loss of $25.4 million for the third quarter 2026, with a loss per share of $0.35 that outperformed analyst expectations. The company is approaching a critical clinical catalyst with topline results for its Phase 2 ALTITUDE-AD trial scheduled for release in November 2026. Financial resources remain constrained, as the current cash position is only projected to support operations into early 2027.
Key Highlights
- Topline results for the Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer's disease are confirmed for a November 2026 release.
- Cash, cash equivalents, and marketable securities decreased to $78.6 million from $110.2 million at the end of the previous quarter.
- Research and development expenses declined to $21.1 million from $22.0 million year-over-year, primarily due to lower manufacturing and CRO costs related to the ALTITUDE-AD trial.